Citizens’ Actions in Response to Chikungunya Outbreaks, Réunion Island, 2006

Bernard-Alex Gaüzère, Jean-Hugues Mausole, Fabrice Simon

Author affiliations: Centre Hospitalier Universitaire, Saint-Denis, Reunion, France (B.-A. Gaüzère); Association des Victimes de l’Épidémie de Chikungunya, Saint-Denis, France (J.-H. Mausole); La Veran Teaching Military Hospital, Marseille, France (F. Simon)

DOI: http://dx.doi.org/10.3201/eid2105.141385

To the Editor: To get ready for the spread of chikungunya, health authorities in North, South, and Central America and the Pacific Islands are developing preparedness and response plans (1,2) that contain vector control, epidemiologic surveillance, medical education, and communication components. They might consider the experience of Réunion Island, an overseas department of France, where a chikungunya outbreak affected 38.5% of its 800,000 inhabitants during the first 3 months of 2006 (3). Although the island was unprepared to deal with such a massive outbreak (4), the disease was under control by the middle of 2006; only a few sporadic cases occurred during the following years. In addition to taking recommended public health measures, public health officials in France created a task force with physicians (including intensive care unit doctors, pediatricians, and obstetricians), specialists in public health and social sciences, virologists, immunologists, entomologists, and pathologists (5) to develop a multidisciplinary approach to the outbreak.

Some citizens’ initiatives complemented the official measures. First, associations of chikungunya virus–infected patients helped families (through means that included psychological and friendly support and home visits) and updated mass media with regard to disease complications, persistent symptoms, and administrative difficulties (including receiving long-term sick leave and disability, recognition of professional exposure, and free analgesic medication). Second, citizens created a chikungunya-dedicated website (http://www.chikungunya.net) that included citizens’ frequently asked questions and university-affiliated physicians’ responses and patients’ forums. Third, citizens actively supported the twice-yearly Kass moustik (Creole for “to break mosquitoes”) operations, which involved vast community mobilizations to educate persons on mosquitoes’ role in spreading chikungunya and to destroy breeding sites near homes. The operations also involved mobilizing community-based and municipality groups, making door-to-door visits, and lobbying for government funds (each operation cost US $60,000). After implementation of these initiatives, telephone operators sent health messages to all cell phones on the island. These actions demonstrate that citizens have a place in their countries’ response to chikungunya outbreaks.

References

Address for correspondence: Fabrice Simon, La Veran Military Teaching Hospital—Tropical Medicine and Infectious Diseases, 34 Boulevard Laveran, BP 50004, 13384 Marseille CEDEX 13, France; e-mail: simon-fi@wanadoo.fr

Loa loa Infection in Pregnant Women, Gabon

Ghyslain Mombo-Ngoma, Jean Rodolphe Mackanga, Arti Basra, Meskure Capan, Rella Zoleko Manego, Ayôla Akim Adegnika, Felix Lötsch, Maria Yazdanbakhsh, Raquel González, Clara Menendez, Barthelemy Mabika, Pierre Blaise Matsiegui, Peter G. Kremsner, Michael Ramharter

Affiliations: Universität Tübingen, Tübingen, Germany (G. Mombo-Ngoma, J.R. Mackanga, A. Basra, M. Capan, R.Z. Manego, A.A. Adegnika, P.B. Matsiegui, P.G. Kremsner, M. Ramharter); Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon (G. Mombo-Ngoma, J.R. Mackanga, A. Basra, M. Capan, A.A. Adegnika, F. Lötsch, P.G. Kremsne, M. Ramharter); Ngounié Medical Research Centre, Fougamou, Gabon (G. Mombo-Ngoma, R.Z. Manego, P.B. Matsiegui); Université des Sciences de la Santé, Libreville, Gabon (G. Mombo-Ngoma, B. Mabika); Leiden University Medical Centre, Leiden, the Netherlands (A.A. Adegnika, M. Yazdanbakhsh); Medical University of Vienna, Vienna, Austria (F. Lötsch, M. Ramharter); Hospital Clinic Universitat de Barcelona, Barcelona, Spain (R. González, C. Menendez)

DOI: http://dx.doi.org/10.3201/eid2105.141471
To the Editor: *Loa loa*, the African eye worm, is a filarial pathogen of Central African rainforest regions. As of 2013, it had affected an estimated 2–3 million persons in Central Africa (1,2). Adult worm migrations in humans may intermittently cause Calabar swelling, and microfilariae are commonly found in blood and body fluids. Loiasis is a chronic infection persisting for many years; a considerable proportion of women in loiasis-endemic regions are infected during gestation. To date, the epidemiology of loiasis in pregnant women has not been investigated, and the effects of loiasis on maternal and fetal health outcomes are unknown. We investigated the epidemiology of loiasis in a cohort of pregnant women participating in a drug trial for preventing malaria during pregnancy.

This study was conducted at the Centre de Recherches Médicales de Lambaréné, Albert Schweitzer Hospital, Lambaréné, Gabon, and at the Ngounié Medical Research Centre, Fougamou, Gabon, during September 2009–April 2012 (3). The filarial pathogens *L. loa* and *Mansonella perstans* are endemic to the study region, which is in the equatorial rainforest, and malaria is hyperendemic in the region (1,4). Study participants were HIV-negative pregnant women in a clinical trial assessing intermittent preventive treatment of malaria during pregnancy (clinical trials identifier: Malaria in Pregnancy Preventative Alternative Drugs [MiPPAD]; NCT00811421) (5). Pregnant women were recruited before their third trimester. After providing written informed consent, they were randomly allocated to receive treatment with either sulfadoxine/pyrimethamine or mefloquine. Ethical clearance was obtained from the Comité d’Éthique Regional Indépendent de Lambaréné.

Women for whom ≥1 microscopic examination of blood revealed microfilariae during the course of their pregnancy were classified as *L. loa* infected. Women were considered aflagemmic if ≥2 blood examination results were negative. Microfilariae were detected by examination of thick and thin blood smears or by saponin leukoconcentration. Examination for placental infection was performed by impression smear of a fresh placental biopsy. Baseline demographic and anthropometric characteristics were recorded at the first antenatal visit and at delivery. Data were double-entered into an electronic database for statistical analysis (STATA/SE 12.1; StataCorp LP, College Station, TX, USA).

Of 1,184 women participating in the antimalarial drug trial, 1,004 contributed data for our analysis. Women who had no record of delivery (n = 120) or who had multiple births (n = 60) were excluded. Of these 1,004 women, *L. loa* microfilariae were found in peripheral blood of 179 (18%); of those, microfilariae were found in placental blood of 24 (13%). No microfilariae were found in the placenta of women with aflagemmic peripheral blood. Loiasis prevalence was higher among older women (≥30 years of age) than among adolescents (14–17 years of age; odds ratio 2.1, 95% CI 1.2–3.9). Microfilaremia was more common among multigravid women than among primigravid women (p = 0.06) but was not associated with other maternal baseline characteristics or with low infant birthweight, preterm births, or adverse delivery outcomes (Table). No histologic evidence of intervillous inflammation, infarcted areas, or chorioamnionitis was observed in the placenta of women with loiasis, and no microfilariae were observed in any examined cord blood samples.

In this study, we attempted to characterize the epidemiology of *L. loa* infection during pregnancy in a highly *L. loa*-endemic region of Central Africa. Microfilaremia was associated with the women’s age, a finding indicating that prevalence increases because of the long duration of infection and continued exposure. The age-related increase in the prevalence of *L. loa* infection aligns with previously reported prevalence and contrasts with age-related prevalence of other parasitic infections (6,7). Anecdotal evidence suggests the potential of *L. loa* worms to invade the placenta (8). In this systematic investigation, microfilarial invasion of the placenta occurred in 13% of microfilaremic patients. However, histopathologic analysis showed no evidence for pathologic alterations of the placenta, and risk for adverse birth outcomes did not increase. Transgression of microfilariae into cord blood was not observed.

This study has limitations. First, misclassification of occult infection is possible because infection status was classified on the basis of the presence of microfilaremia. Also, antimalarial drugs routinely administered during pregnancy may have influenced the course of loiasis, as has been shown for other helminth infections (9,10). Further, the observational study design creates difficulties in establishing a causal relationship between infection status and birth outcomes because of possible confounding factors. Additional research is needed to disentangle the association among pregnancy outcomes, socioeconomic conditions, and pathophysiologic consequences of *L. loa* infection in pregnant women.

Results of this prospective study show a high prevalence of loiasis among pregnant women in a loiasis-endemic region in Central Africa. The invasion of microfilariae into the intervillous space of the placenta is a newly described feature of pregnancy-associated loiasis. These data can be used as a starting point for further epidemiologic and clinical research activities investigating this neglected filarial infection in pregnant women in Central Africa.

**Acknowledgments**

We thank the management team and the participants of the MiPPAD study along with the logistical and infrastructure support provided by the Central African Network for Tuberculosis, HIV/AIDS, and Malaria.
The main clinical trial (MiPPAD) was funded by a grant from the European & Developing Countries Clinical Trials Partnership (EDCTP2.P07.13080.002), Germany’s Federal Ministry of Education and Research (FKZ: 01KA0803), and the Malaria in Pregnancy Consortium, which is funded by a grant from the Bill and Melinda Gates Foundation to the Liverpool School of Tropical Medicine.

References


Address for correspondence: Michael Ramharter, Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria; email: michael.ramharter@meduniwien.ac.at